Taylor Frigon Capital Management LLC Trims Stock Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Taylor Frigon Capital Management LLC lowered its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 43.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 212,246 shares of the company's stock after selling 162,551 shares during the period. ClearPoint Neuro makes up 1.6% of Taylor Frigon Capital Management LLC's portfolio, making the stock its 17th largest holding. Taylor Frigon Capital Management LLC owned 0.77% of ClearPoint Neuro worth $3,264,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of ClearPoint Neuro by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 287,294 shares of the company's stock worth $3,222,000 after purchasing an additional 4,170 shares in the last quarter. Conway Capital Management Inc. grew its position in shares of ClearPoint Neuro by 13.9% during the 4th quarter. Conway Capital Management Inc. now owns 161,225 shares of the company's stock worth $2,480,000 after purchasing an additional 19,725 shares in the last quarter. Parsons Capital Management Inc. RI grew its position in shares of ClearPoint Neuro by 1.9% during the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock worth $2,177,000 after purchasing an additional 2,600 shares in the last quarter. Bradley Foster & Sargent Inc. CT acquired a new position in shares of ClearPoint Neuro during the 4th quarter worth approximately $871,000. Finally, Pekin Hardy Strauss Inc. acquired a new stake in shares of ClearPoint Neuro during the 3rd quarter worth approximately $541,000. Institutional investors and hedge funds own 30.08% of the company's stock.

Remove Ads

ClearPoint Neuro Price Performance

NASDAQ CLPT traded up $0.32 during mid-day trading on Friday, reaching $14.52. 346,046 shares of the stock were exchanged, compared to its average volume of 230,075. The stock has a market cap of $401.22 million, a P/E ratio of -21.04 and a beta of 1.03. The stock has a 50 day simple moving average of $16.64 and a 200-day simple moving average of $13.87. ClearPoint Neuro, Inc. has a one year low of $5.11 and a one year high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). The company had revenue of $7.77 million during the quarter, compared to analyst estimates of $8.23 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. Sell-side analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CLPT. B. Riley increased their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Lake Street Capital raised their price target on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, January 21st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.